Business Wire
-
DNAnexus Adds NVIDIA NIM And CUDA-X Microservices To Precision Health Data Cloud To Accelerate Drug Discovery And Improve Patient Care
3/19/2024
DNAnexus, Inc., the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices.
-
U.S. Food And Drug Administration (FDA) Has Accepted The New Drug Application (NDA) For Ensartinib
3/13/2024
Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).
-
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
3/11/2024
AbCellera and Biogen Inc. have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
-
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
3/11/2024
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).
-
Verastem Oncology Receives Orphan Drug Designation From FDA For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
3/5/2024
Verastem Oncology a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, alone or in combination with defactinib, a selective FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC).
-
bit.bio Announces First Project Within Multi-Year Collaboration Agreement With The Michael J. Fox Foundation (MJFF) To Generate Human Cell Products For Research And Drug Discovery In Parkinson’s Disease
3/5/2024
bit.bio, the company coding human cells for novel cures, today announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease (PD).
-
AnHeart Therapeutics And Innovent Announce China’s NMPA Has Accepted Second New Drug Application For Taletrectinib For First-Line Treatment Of ROS1-Positive Lung Cancer
3/4/2024
AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, and Innovent Biologics, Inc. (“Innovent”) a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a second New Drug Application (NDA) for taletrectinib, a
-
Microsoft And 1910 Genetics Partner To Build The Infrastructure Layer For Drug Discovery And Development Using AI And High-Performance Computing
2/29/2024
1910 Genetics (or “1910”), the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation, today announced a new five-year commercial agreement and go-to-market collaboration with Microsoft to harness advanced artificial intelligence (AI) and next-generation, high-performance computing (HPC) to reverse 70 years of declining pharmaceutical R&D productivity.
-
Everest Medicines And Kezar Life Sciences Receive IND Approval From China NMPA For PALIZADE Trial In Lupus Nephritis
2/26/2024
Everest Medicines and Kezar Life Sciences, Inc. announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
-
Ligand Partner Eisai Receives Approval In Japan For Injection Formulation Of Antiepileptic Drug Fycompa
2/22/2024
Ligand Pharmaceuticals Incorporated today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.